Grimes & Company, Inc. Incyte Corp Call Options Transaction History
Grimes & Company, Inc.
- $3.66 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INCY
# of Institutions
642Shares Held
186MCall Options Held
714KPut Options Held
557K-
Baker Bros. Advisors LP New York, NY30.7MShares$2.17 Billion21.76% of portfolio
-
Black Rock Inc. New York, NY21.4MShares$1.51 Billion0.03% of portfolio
-
Vanguard Group Inc Valley Forge, PA20.4MShares$1.44 Billion0.02% of portfolio
-
Dodge & Cox San Francisco, CA15.3MShares$1.08 Billion0.61% of portfolio
-
State Street Corp Boston, MA10.6MShares$744 Million0.03% of portfolio
About INCYTE CORP
- Ticker INCY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 222,431,008
- Market Cap $15.7B
- Description
- Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...